Clinical trial
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney…
NCT00132431 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00132431 |
|---|---|
| Title | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism |
| Official title | Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | Sensipar |
| Enrollment | 300 |
| Start date | Jul 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Aug 22, 2005 |
| Last update posted | Feb 13, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: